Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Probiotics for COVID-19: real-time meta analysis of 20 studies
Covid Analysis, December 2022
https://c19early.org/kmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Haran (RCT) 67% 0.33 [0.01-8.16] death 0/174 1/176 Improvement, RR [CI] Treatment Control Haran (RCT) 60% 0.40 [0.08-2.06] hosp. 2/174 5/176 Haran (RCT) 50% 0.50 [0.21-1.20] hosp./ER/UC 7/169 15/181 Haran (RCT) 20% 0.80 [0.61-1.04] recov. time 169 (n) 172 (n) Gutiérre.. (DB RCT) 35% 0.65 [0.53-0.80] no recov. 69/147 105/146 Veterini 29% 0.71 [0.41-1.22] viral time 15 (n) 15 (n) Navarro-Ló.. (RCT) 33% 0.67 [0.43-1.05] no recov. 14/24 13/15 Navarro-Ló.. (RCT) 53% 0.47 [0.20-1.08] no recov. 6/24 8/15 Navarro-Ló.. (RCT) 20% 0.80 [0.65-0.98] recovery 24 (n) 15 (n) Navarro-Ló.. (RCT) 26% 0.74 [0.54-1.01] recovery 24 (n) 15 (n) d'Ettorre 87% 0.13 [0.01-2.33] death 0/28 4/42 d'Ettorre 77% 0.23 [0.01-4.63] ventilation 0/28 2/42 d'Ettorre 88% 0.12 [0.02-0.61] progression 28 (n) 42 (n) Ceccarelli 64% 0.36 [0.18-0.68] death 10/88 34/112 Ceccarelli 15% 0.85 [0.48-1.50] ICU 16/88 24/112 Shah (RCT) 11% 0.89 [0.75-1.06] recov. time 30 (n) 30 (n) CT​1 Shah (RCT) 11% 0.89 [0.76-1.05] hosp. time 30 (n) 30 (n) CT​1 Shah (RCT) 83% 0.17 [0.04-0.68] no recov. 2/30 12/30 CT​1 Shah (RCT) 4% 0.96 [0.80-1.16] no recov. 26/30 27/30 CT​1 Li -12% 1.12 [0.74-1.69] no disch. 30/123 41/188 Li -60% 1.60 [1.21-2.11] no disch. 123 (n) 188 (n) Li -35% 1.35 [1.13-1.62] viral time 123 (n) 188 (n) Zhang 14% 0.86 [0.77-0.96] hosp. time 150 (n) 150 (n) Zhang 14% 0.86 [0.75-0.98] recov. time 150 (n) 150 (n) Zhang 17% 0.83 [0.75-0.93] viral time 150 (n) 150 (n) Ceccarelli 70% 0.30 [0.01-7.02] death 0/40 1/29 Ceccarelli 82% 0.18 [0.02-1.54] ICU 1/40 4/29 Ivashkin (RCT) -2% 1.02 [0.26-3.97] death 4/99 4/101 Ivashkin (RCT) 18% 0.82 [0.23-2.95] ventilation 4/99 5/101 Ivashkin (RCT) 27% 0.73 [0.24-2.22] ICU 5/99 7/101 Ivashkin (RCT) 5% 0.95 [0.84-1.08] recov. time 99 (n) 101 (n) Zhang 65% 0.35 [0.02-8.30] ventilation 0/25 1/30 Zhang 67% 0.33 [0.10-1.05] antibody 3/25 11/30 Saviano (RCT) 67% 0.33 [0.01-7.95] death 0/40 1/40 Saviano (RCT) 86% 0.14 [0.01-2.68] ICU 0/40 3/40 Saviano (RCT) 26% 0.74 [0.30-1.83] hosp. time 40 (n) 40 (n) Trinchieri 78% 0.22 [0.03-1.93] death 1/21 3/14 Trinchieri 78% 0.22 [0.09-0.55] misc. 4/21 12/14 Trinchieri 10% 0.90 [0.76-1.08] misc. 19/21 14/14 Louca 8% 0.92 [0.85-0.99] cases Di Pierro (RCT) 98% 0.02 [0.00-0.33] cases 0/64 24/64 Holt 30% 0.70 [0.45-1.10] cases 20/909 426/14,318 Ahanchian (DB RCT) 73% 0.27 [0.03-2.25] symp. case 1/29 4/31 Ahanchian (DB RCT) 85% 0.15 [0.01-2.73] cases 0/29 3/31 Wischme.. (DB RCT) 33% 0.67 [0.38-1.17] m/s case 16/91 24/91 Wischme.. (DB RCT) 38% 0.62 [0.41-0.93] symp. case 24/91 39/91 Wischme.. (DB RCT) 27% 0.73 [0.37-1.45] recov. time 91 (n) 91 (n) Wischme.. (DB RCT) 43% 0.57 [0.25-1.30] cases 8/91 14/91 Rodrigue.. (DB RCT) 9% 0.91 [0.12-6.70] cases 2/127 2/128 Probiotics COVID-19 outcomes c19early.org/k Dec 2022 1 CT: study uses combined treatment Favors probiotics Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit